Luma Maria Tavares de Sousa

Luma Maria Tavares de Sousa

Auto-generated profile, based on publicly available information

Luma Maria Tavares de Sousa

Hospital de Messejana Dr. Carlos Alberto Studart Gomes, Fortaleza, Ceará, Brazil; Universidade Federal do Ceará, Fortaleza, Ceará, Brazil

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Open Heart
Verified
Journal Article
Open access
PDF file
TCThomaz Alexandre Costa
Thomaz Alexandre Costa
GCGabriel Cavalcante Lima Chagas
Gabriel Cavalcante Lima Chagas
LSLuma Maria Tavares de Sousa
Luma Maria Tavares de Sousa
BSBruno Lins de Souza
Bruno Lins de Souza
NFNicole Felix
Nicole Felix
BLBruno Bezerra Lima
Bruno Bezerra Lima
Background: Left ventricular (LV) thrombus is a complication of myocardial infarction and dilated cardiomyopathy and is associated with a high thromboembolic risk. Although warfarin has traditionally been used, direct oral anticoagulants (DOACs) offer a more convenient alternative. With the addition of the RIVAWAR trial, we conducted an updated systematic review and meta-analysis to assess the efficacy and safety of DOACs compared with warfarin in patients with LV thrombus. Methods: A systematic search of electronic databases (PubMed, EMBASE, Cochrane and clinicaltrials.gov) from inception to April 2025 identified randomised clinical trials (RCTs) comparing DOACs with warfarin for the treatment of LV thrombus. The main outcome of interest was thrombus resolution at 3 months. Risk ratios (RRs) with 95% CIs were calculated using random-effects models. Results: Seven RCTs comprising 554 patients were included. Non-contrast transthoracic echocardiography was used for LV thrombus assessment in all RCTs. There was no difference between DOACs and warfarin in thrombus resolution at 3 months (RR 1.02; 95% CI 0.95 to 1.09), major adverse cardiovascular events (RR 0.50; 95% CI 0.16 to 1.54), all-cause mortality (RR 0.92; 95% CI 0.36 to 2.31), stroke/systemic embolism (RR 0.76; 95% CI 0.12 to 4.68), rehospitalisation (RR 1.36; 95% CI 0.47 to 3.94) or major bleeding (RR 0.54; 95% CI 0.20 to 1.48). Subgroup and sensitivity analyses confirmed the robustness of these results. Conclusions: DOACs demonstrated similar efficacy and safety to warfarin for LV thrombus management in this meta-analysis, supporting their use for the treatment of LV thrombus. However, large-scale RCTs with longer follow-up periods and using diagnostic modalities with higher sensitivity and specificity for detecting LV thrombus resolution are warranted to confirm these findings and clarify long-term outcomes. PROSPERO registration number: CRD420251023513.

30 September 2025 in Interventional Neuroradiology
Verified
Journal Article
Closed access
JSJoão Victor Sanders
João Victor Sanders
LSLuma Maria Tavares de Sousa
Luma Maria Tavares de Sousa
ODOcílio de Deus
Ocílio de Deus
MOMarion Oliver
Marion Oliver
RNRaul G Nogueira
Raul G Nogueira
KJKrishna Joshi
Krishna Joshi
Background: Endovascular therapy (EVT) improves functional outcomes and reduces mortality in acute ischemic stroke (AIS) due to basilar artery occlusion (BAO). However, data on hemorrhagic complications and nonneurologic adverse events remain limited. We conducted a systematic review and meta-analysis to assess these outcomes in randomized controlled trials (RCTs) comparing EVT versus best medical management (BMM). Methods: We searched PubMed, Cochrane Library, and Embase in December 2024 for RCTs comparing EVT and BMM (PROSPERO registry CRD42024617681). Outcomes included any parenchymal hematoma (PH), PH type 1 and 2, subarachnoid hemorrhage (SAH), systemic/extracranial hemorrhage, pneumonia, and heart failure. Pooled risk ratios (RR) with 95% confidence intervals (CI) were calculated using a random-effects model. Results: Four RCTs, 988 patients (556 EVT, 432 BMM), were included. EVT increased the risk of SAH (RR 5.14; 95% CI [1.35–19.56]; I² = 0.0%) and PH type 2 (RR 5.53; 95% CI [1.47–20.84]; I² = 0.0%) compared to BMM. No significant differences were observed for any PH (RR 1.91; 95% CI [0.92–3.97]; I² = 0.0%), PH type 1 (RR 0.71; 95% CI [0.22–2.29]; I² = 3.4%), systemic/extracranial hemorrhage (RR 1.06; 95% CI [0.71–1.60]; I² = 12.2%), pneumonia (RR 1.00; 95% CI [0.83–1.21]; I² = 0.0%), or heart failure (RR 2.00; 95% CI [0.34–11.92]; I² = 55.4%). Conclusion: In patients with BAO AIS, EVT is associated with an increased risk of SAH and PH type 2 compared with BMM. There was no significant difference in any PH, PH type 1, systemic/extracranial hemorrhage, pneumonia, and heart failure between groups.

14 July 2026 in Transplantation Proceedings
Verified
Journal Article
Closed access
JVJefferson Luís Vieira
Jefferson Luís Vieira
DFDhayn Cassi de Almeida Freitas
Dhayn Cassi de Almeida Freitas
LSLuma Maria Tavares de Sousa
Luma Maria Tavares de Sousa
LALorena Alves de Souza Leal de Araújo
Lorena Alves de Souza Leal de Araújo
EAEline Pereira Alves
Eline Pereira Alves
JNJoão David de Souza Neto
João David de Souza Neto